The Company seeks to be an innovative technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a variety of ailments. The Company is developing and utilizing state of the art technologies in plant biology, cultivation and extraction techniques, combined with biotechnology, and plans to produce consistent and measurable medical grade cannabis, cannabis concentrates and cannabinoid therapies. Although we believe that maximum shareholder value will ultimately be achieved through the development, production and marketing of certified cannabinoid medicines, therapies and treatments, in order to generate cash flow and near term profitability, we intend to cultivate and dispense cannabis for medical purposes in both Nevada and other states which permit such sales and in which we and our operating partners are able to obtain cultivation and dispensing licenses. We seek to become a trusted producer of consistent and efficacious medicinal strains and products, combining both cannabinoids and terpenes, which we intend to market in those states within the United States and in other countries where the sale of medical cannabis products are permitted. In addition, subject to obtaining Food and Drug Administrative FDA certification, we intend to market our cannabinoid based drug discoveries on a world wide basis.
Quote | GB Sciences Inc (OTCMKTS:GBLX)
Last: | $0.0067 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0055 |
Close: | $0.0067 |
High: | $0.0067 |
Low: | $0.0055 |
Volume: | 29,383 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | GB Sciences Inc (OTCMKTS:GBLX)
LAS VEGAS, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infect...
LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which...
Message Board Posts | GB Sciences Inc (OTCMKTS:GBLX)
Subject | By | Source | When |
---|---|---|---|
I wonder how far out they are from | loanshark007 | investorshub | 04/06/2023 9:26:51 PM |
No, I believe he is with $INQD now. | loanshark007 | investorshub | 04/06/2023 9:26:07 PM |
$GBLX has not been discovered yet. $GBLX | SmallCapStockAlert | investorshub | 03/15/2023 4:11:45 PM |
Is leslie bockor is on the board of directors?? | Think1st | investorshub | 03/12/2023 3:18:50 AM |
$GBLX #AI is a biotech gamechanger and $GBLX | SmallCapStockAlert | investorshub | 02/25/2023 4:11:33 PM |
News, Short Squeeze, Breakout and More Instantly...
LAS VEGAS, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infect...
LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which...
LAS VEGAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Food and Chemical Toxicology that demonstrates the potential of selec...